Archive
Issues
Dilation safety and medication-associated angle-closure risk
- Plus OCT rules in myopia, nicotinamide exposure, trabeculectomy versus Baerveldt, and ophthalmology news.
10-2 visual fields and fast central glaucoma progression
- Plus UBE2E3 steroid genetics, tirzepatide glaucoma risk, fast Asian NTG, and ophthalmology news.
PGA use and pseudophakic CME after cataract surgery
- Plus endophthalmitis rates, XEN45 cost-effectiveness, Envision VR perimetry, and ophthalmology news.
HORIZON IOP control and VF progression
- Plus 24-hour blood pressure, denosumab risk associations, MIGS payment shifts, and ophthalmology news.
Polygenic risk score stratifies glaucoma risk and treatment burden
- Plus repeat IOP variability, specialist access gaps, eyedrop storage, and ophthalmology news.
Home tonometry showed prostaglandin washout may exceed 4 weeks
- Plus polygenic risk, risk-based suspect monitoring, OSA-linked glaucoma risk, and ophthalmology news.
Iris trabecular contact on OCT in angle closure progression
- Plus pharmacy-based adherence risk, goniotomy outcomes, hemodialysis treatment risk, and ophthalmology news.
MIGS shows similar 2-year success rates in secondary glaucoma
- Plus drop-adherence coaching, 15-year OAG incidence, delayed follow-up, and ophthalmology news.
Bevacizumab improves 3-year trabeculectomy survival
- Plus brimonidine and trabeculectomy failure, myopia surgery risk, NLP follow-up gaps, and ophthalmology news.
Macular OCT in later glaucoma progression
- Plus keratoplasty risk after glaucoma treatment, OAG risk factors, and nicotinamide in NTG.
Pigmentary glaucoma fails SLT and MIGS more often
- Plus post-LPI steroids, frontloaded VF testing, and PDE-5 inhibitor/OAG risk.
Primary trabeculectomy halves VF loss
- Plus PXF without elevated IOP, a 12-year retinomics model, and niacin-B12 lowering OAG.
Weekly newsletter
Get the weekly newsletter in your inbox.
New issues land in the inbox first. The archive is here when you want to revisit or share a specific issue.
SubscribeOne issue each week. Unsubscribe anytime.